Page 72 - 《中国药科大学学报》2025年第4期

468 学报 Journal of China Pharmaceutical University 2025, 56(4): 460 − 468 第 56 卷

[26]
常的 30% 以下 ，且与白蛋白结合率降低，游离药 2025, 16: 1233.
物浓度升高 [27] 。甲钴胺主要经肾脏排泄，而肝衰竭 [11] China Pharmaceutical University. Use of Mecobalamin and
Pharmaceutical Compositions in the Preparation of Drugs for
合并肝肾综合征时肾小球滤过率降低，可能影响其 Treating Liver Failure: CN, 115998758A[P]. 2023-04-25.
排泄过程。鉴于健康患者和肝衰竭患者在药物药 [12] Alpers DH, Russell-Jones G. Gastric intrinsic factor: the gastric
and small intestinal stages of cobalamin absorption. a personal
代动力学行为上存在明显差异，这种差异对药物疗
journey[J]. Biochimie, 2013, 95(5): 989-94.
效和毒性反应有着重要影响，值得深入关注。后续 [13] Seetharam B, Yammani RR. Cobalamin transport proteins and
研究将借助肝衰竭模型大鼠，系统研究甲钴胺和头 their cell-surface receptors[J]. Expert Rev Mol Med, 2003,
5(18): 1-18.
孢曲松钠的药代动力学行为，阐明两药在肝衰竭状
[14] Popick AC, Crouthamel WG, Bekersky I. Plasma protein bind-
态下的药代动力学特征。 ing of ceftriaxone[J]. Xenobiotica, 1987, 17(10): 1139-1145.

[15] Patel IH, Kaplan SA. Pharmacokinetic profile of ceftriaxone in
5 结 论 man[J]. Am J Med, 1984, 77(4C): 17-25.
[16] The International Council for Harmonisation of Technical Re-
本实验分别建立了 SD 大鼠血浆中甲钴胺和 quirements for Pharmaceuticals for Human Use. ICH M10-
头孢曲松钠定量分析的 LC-MS/MS 方法并对其进 2022[S]. Center for Drug Evaluation, 2022.
[17] Juzeniene A, Nizauskaite Z. Photodegradation of cobalamins in
行了方法学考察。药代动力学研究表明，与单次单
aqueous solutions and in human blood[J]. J Photochem Photo-
独给药相比，单次联合给药下两药在健康大鼠体内 biol B, 2013, 122: 7-14.
的药代动力学行为无显著性差异，表明甲钴胺与头 [18] Ao ZX, Feng SS, Zhao CY, et al. Study on polycyclic macro-
molecular drug solid stability: a case exploration of methyl-
孢曲松钠进行联合用药时，无基于药代动力学的药
cobalamin[J]. Int J Pharm, 2023, 644: 123326.
物相互作用。 [19] Xu QA, Trissel LA, Williams KY. Compatibility and stability
of linezolid injection admixed with three cephalosporin antibi-
otics[J]. J Am Pharm Assoc (Wash), 2000, 40(4): 509-514.
References
[20] Gruber K, Puffer B, Kräutler B. Vitamin B12-derivatives-en-
[1] Perricone G, Artzner T, De Martin E, et al. Intensive care man- zyme cofactors and ligands of proteins and nucleic acids[J].
agement of acute-on-chronic liver failure[J]. Intensive Care Chem Soc Rev, 2011, 40(8): 4346-4363.
Med, 2023, 49(8): 903-921. [21] Thakare R, Chhonker YS, Gautam N, et al. Quantitative analy-
[2] Lemmer P, Pospiech JC, Canbay A. Liver failure-future chal- sis of endogenous compounds[J]. J Pharm Biomed Anal, 2016,
lenges and remaining questions[J]. Ann Transl Med, 2021, 9(8): 128: 426-437.
734. [22] Gachet MS, Rhyn P, Bosch OG, et al. A quantitiative LC-
[3] Kumar R, Anand U, Priyadarshi RN. Liver transplantation in MS/MS method for the measurement of arachidonic acid,
acute liver failure: Dilemmas and challenges[J]. World J Trans- prostanoids, endocannabinoids, N-acylethanolamines and
plant, 2021, 11(6): 187-202. steroids in human plasma[J]. J Chromatogr B Analyt Technol
[4] Ye C, Li WY, Li L, et al. Glucocorticoid treatment strategies in Biomed Life Sci, 2015, 976/977: 6-18.
liver failure[J]. Front Immunol, 2022, 13: 846091. [23] Caraceni P, Tufoni M, Zaccherini G, et al. On-treatment serum
[5] Zeng J, Fan JG, Zhou HP. Bile acid-mediated signaling in albumin level can guide long-term treatment in patients with cir-
cholestatic liver diseases[J]. Cell Biosci, 2023, 13(1): 77. rhosis and uncomplicated ascites[J]. J Hepatol, 2021, 74(2):
[6] Allison R, Guraka A, Shawa IT, et al. Drug induced liver in- 340-349.
jury–a 2023 update[J]. J Toxicol Environ Health Part B, 2023, [24] Guévin C, Michaud J, Naud J, et al. Down-regulation of hepat-
26(8): 442-467. ic cytochrome p450 in chronic renal failure: role of uremic me-
[7] Zhang YF, Ning G. Mecobalamin[J]. Expert Opin Investig diators[J]. Br J Pharmacol, 2002, 137(7): 1039-1046.
Drugs, 2008, 17(6): 953-964. [25] Canet MJ, Cherrington NJ. Drug disposition alterations in liver
[8] Shibuya K, Misawa S, Nasu S, et al. Safety and efficacy of in- disease: extrahepatic effects in cholestasis and nonalcoholic
travenous ultra-high dose methylcobalamin treatment for pe- steatohepatitis[J]. Expert Opin Drug Metab Toxicol, 2014,
ripheral neuropathy: a phase I/II open label clinical trial[J]. In- 10(9): 1209-1219.
tern Med, 2014, 53(17): 1927-1931. [26] Stoeckel K, Koup JR. Pharmacokinetics of ceftriaxone in pa-
[9] Ganguly A, de la Flor C, Alvarez K, et al. Safety and efficacy of tients with renal and liver insufficiency and correlations with a
ceftriaxone in the treatment of methicillin-susceptible Staphylo- physiologic nonlinear protein binding model[J]. Am J Med,
coccus aureus bloodstream infections: a noninferiority retro- 1984, 77(4C): 26-32.
spective cohort study[J]. Ann Pharmacother, 2023, 57(4): 425- [27] Comce MH, Weersink RA, Beuers U, et al. Pharmacokinetics of
431. ceftriaxone, gentamicin, meropenem and vancomycin in liver
[10] Xu WF, Wang Y, Cui S, et al. Methylcobalamin protects cirrhosis: a systematic review[J]. J Antimicrob Chemother,
against liver failure via engaging gasdermin E[J]. Nat Commun, 2024, 79(11): 2750-2761.